22 May 2022 , 02:05 PM
Result date: 23rd May, 2022
Recommendation: Reduce
Target price: Rs3,720
Divis Laboratories (Divis) is likely to post muted performance in the March 2022 quarter on a sequential basis. This weakness will largely stem from a sharp 32% sequential decline in Molnupiravir revenue. The company’s exports of Molnupiravir API have declined from a monthly average of USD40-45 million in the December 2021 quarter to ~USD20 million in February 2022, implying a 50% decline in the monthly run-rate. While its Molnupiravir API export volumes have declined, its price has remained steady at USD1500/kg for the past 3 months. The company’s Molnupiravir API revenue could decline from ~USD105 million in December 2021 quarter to ~USD70 million in the March 2022 quarter. Consequently, Divis’ overall revenue will likely decline 6% sequentially (total revenue could increase ~31% over the year-ago quarter).
Divis has also seen pricing pressures on two of its largest generic API products, with average pricing for Naproxen (~40% of Divis' generic API revenue) and Dextromethorphan (~14% of Divis' generic API revenue) being down ~9% and ~15%, respectively, in FY22, which has also impacted growth of its base generic API business.
Weak revenue could lead to decline in EBITDA as well as Profit After Tax (PAT) on a sequential basis.
Important management insights to watch out for:
· New launch pipeline
· Likely full contribution from new launches
· Margin drivers in the future
Rs Million | March 2022 estimates | YoY change | QoQ change |
Revenue | 23,432 | 31% | (6)% |
EBITDA | 10,076 | 41% | (8)% |
Profit After Tax | 7,098 | 41% | (21)% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.